SCHEMBL3224846

SCHEMBL3224846

O=C1NCC(C2CCC2)c2[nH]c3c(ccc4cnccc43)c21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.53
CDK9 P50750 2/20 0.41
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
PRKCZ Q05513 4/20 0.36
PRKACA P17612 3/20 0.36
PRKCD Q05655 3/20 0.36
ROCK2 O75116 3/20 0.36
ROCK1 Q13464 3/20 0.36
DAPK3 O43293 2/20 0.36
CHEK2 O96017 2/20 0.36
RPS6KB1 P23443 2/20 0.36
AKT1 P31749 2/20 0.36
RPS6KA3 P51812 2/20 0.36
CDK5 Q00535 2/20 0.36
AURKB Q96GD4 2/20 0.36
PRKD2 Q9BZL6 2/20 0.36
SGK2 Q9HBY8 2/20 0.36
AKT3 Q9Y243 2/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222912 0.80 CDC7 (0.53) CDC7CDK9CDK4CCND1PRKCZ
SCHEMBL3226801 0.78 CDC7 (0.54) CDC7CDK9CDK4CCND1PRKCZ
SCHEMBL3224855 0.76 CDC7 (0.52) CDC7CDK4CCND1PRKCZPRKACA
SCHEMBL3222681 0.76 CDC7 (0.49) CDC7CDK9CDK4CCND1PRKCZ
SCHEMBL3632140 0.71 CDC7 (0.76) CDC7CDK4CCND1PRKCZPRKACA
SCHEMBL3574892 0.70 CDC7 (0.85) CDC7CDK4CCND1PRKCZPRKACA
SCHEMBL3231573 0.69 CDC7 (1.00) CDC7CDK4CCND1PRKCZPRKACA
SCHEMBL3222669 0.69 CDC7 (0.60) CDC7CDK4CCND1PRKCZPRKACA
Hydrochloric Acid SCHEMBL16872486 0.69 CDC7 (0.97) CDC7CDK9CDK4CCND1PRKCZ
SCHEMBL3225560 0.67 CDC7 (0.68) CDC7CDK4CCND1PRKCZPRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120933-B1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2015-07-08 EP claimed
US-8293762-B2 Isoquinolinopyrrolopyridinones active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-23 US claimed
US-20100056556-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-04 US claimed
EP-2120933-B1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2015-07-08 EP disclosed
US-8293762-B2 Isoquinolinopyrrolopyridinones active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-23 US disclosed
US-20100056556-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056556-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS CDK2, CDK1, CDK3 CDC7 118/4885CDK9 9/4885CDK4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.